J Biol Chem, Vol. 275, Issue 13, 9256-9262, March 31, 2000
Structural Defects Underlying Protein Dysfunction in Human
Glucose-6-phosphate Dehydrogenase A
Deficiency*
Félix
Gómez-Gallego,
Amando
Garrido-Pertierra, and
José M.
Bautista
From the Departamento de Bioquímica y Biología
Molecular IV, Universidad Complutense de Madrid, Ciudad Universitaria,
Facultad de Veterinaria, 28040 Madrid, Spain
 |
ABSTRACT |
The enzyme variant glucose-6-phosphate
dehydrogenase (G6PD) A
, which gives rise to human
glucose-6-phosphate dehydrogenase deficiency, is a protein of markedly
reduced structural stability. This variant differs from the normal
enzyme, G6PD B, in two amino acid substitutions. A further nondeficient
variant, G6PD A, bears only one of these two mutations and is
structurally stable. In this study, the synergistic structural defect
in recombinant G6PD A
was reflected by reduced unfolding
enthalpy due to loss of
-sheet and
-helix interactions where both
mutations are found. This was accompanied by changes in inner spatial
distances between residues in the coenzyme domain and the partial
disruption of tertiary structure with no significant loss of secondary
structure. However, the secondary structure of G6PD A
was
qualitatively affected by an increase in
-sheets substituting
-turns related to the lower unfolding enthalpy. The structural changes observed did not affect the active site of the mutant proteins,
since its spatial position was unmodified. The final result is a loss
of folding determinants leading to a protein with decreased
intracellular stability. This is suggested as the cause of the enzyme
deficiency in the red blood cell, which is unable to perform de
novo protein synthesis.
 |
INTRODUCTION |
The human gene that codes for glucose-6-phosphate dehydrogenase
(G6PD)1 presents many
genetic, pathological, and structural features that make it
particularly suitable for the investigation of relationships between
mutations and protein dysfunction. The human G6PD gene is located on
the X chromosome in a region showing a high degree of genetic
variability. More than 100 mutations or combined mutations associated
with nearly 200 variants have been detected (1). Further, it is
estimated that over 400 million people in the world are G6PD-deficient
(2), making this deficiency the most common human enzymopathy. G6PD
deficiency is associated with acute or chronic hemolytic anemia and
neonatal jaundice. Some genetic variants have attained a high incidence
in certain parts of the world, since they confer selective advantage
against malaria (3, 4).
G6PD catalyzes the oxidation of glucose-6-phosphate to
6-phosphoglucono-
-lactone with the concomitant reduction of NADP to NADPH. NADPH is the only source of reducing power in red blood cells,
where it is required to maintain the redox equilibrium and, in
particular, to detoxify hydrogen peroxide and other compounds via
glutathione (reviewed in Ref. 5).
In African populations or those of African ancestry, the most common
polymorphic variant associated with the deficiency is G6PD
A
, which accounts for 20-40% of the affected population
in western and central Africa (6). This variant differs from the normal G6PD B in that it has two amino acid substitutions, V68M and N126D, which were early identified (7, 8). Furthermore, the most common
nondeficient polymorphic variant in Africa, G6PD A, bears a single
amino acid replacement, N126D, which is also present in G6PD
A
. Nevertheless, the deficient G6PD A
mutation at position 68 alone has not been detected in any variant. This and further haplotyping analyses have led to a suggestion that the
nondeficient single mutant G6PD A is more ancient than the deficient
double mutant G6PD A
(2). Clinically, the G6PD A enzyme
produces no adverse effects in erythrocytes. However, the presence of
the second amino acid substitution in G6PD A
leads to a
90% loss of activity with respect to the normal G6PD B (6).
The three-dimensional model proposed for human G6PD (9) shows that the
mutations at positions 68 and 126 are only 8 Å apart, suggesting an
interactive effect between substitutions as the origin of the deficient
G6PD A
phenotype. The positions of the substitutions
distant from substrate binding and catalytic centers (9), coupled with
the fact that the purified enzyme shows normal specific activity (6)
with unchanged Km values for its substrates (10,
11), lends further support to the idea that the two mutations in G6PD A
notably affect the intracellular stability of the
enzyme in a synergistic manner (12). It has been previously shown that
these two mutations considerably hinder the in vitro
refolding capacity of the enzyme molecule to the point that it prevents
the formation of the catalytically active dimer (13). In contrast, the
presence of the single mutation in G6PD A does not affect refolding
capacity or the consequent formation of active molecules (13).
The use of x-ray diffraction to examine discrete dysfunction effects of
large mutant proteins is limited by the fact that the lattice energy of
crystals is smaller than that stabilizing the protein molecules in
solution and therefore not enough to significantly disturb internal
structures by single amino acid substitutions (14). In an effort to
determine the structural lesions responsible for instability in the
deficient G6PD A
molecule leading to low enzyme activity
levels in the red blood cell, the aim of this investigation was to
perform a complete structural analysis of this protein and to compare
it to its ancestral normal phenotypic variants G6PD B and G6PD A.
 |
EXPERIMENTAL PROCEDURES |
Mutagenesis, Protein Purification, and Sample
Preparation--
The constructs based on the plasmid pKK233-2
containing full-length human cDNA coding for normal G6PD and for
the G6PD A (N126D) and G6PD A
(N126D and V68M) variants
have been previously described (12, 15). Wild-type G6PD B and its
variants were purified to homogeneity by affinity chromatography on
2',5'-ADP Sepharose 4B as described elsewhere (12, 15). The purity of
the enzyme preparations was confirmed by SDS-PAGE. G6PD activity assays
were performed at 30 °C by measuring the increase in absorbance at
340 nm (6). Protein samples used for CD, fluorescence, and
activity assays were dialyzed and equilibrated at 4 °C against 10 mM Tris-HCl, pH 8.0, 5 mM EDTA, 0.02%
2-mercaptoethanol, 1 µM
-aminocaproic acid, and 1 nM NADP. In the experiments conducted in the presence of
urea, the protein samples were preincubated with various denaturant concentrations at 25 °C for 2 h.
Circular Dichroism and Fluorescence--
CD spectra were
obtained at 25 °C in the far-UV (200-250-nm) and near-UV
(250-300-nm) regions using 0.2-cm path length cuvettes. The protein
concentration used to record the spectra was 16.6 µM.
Ellipticity, [
], expressed in terms of mean residue ellipticity (deg·cm2·dmol-1), at 222 and 270 nm, was
calculated as follows,
|
(Eq. 1)
|
where MRW represents the mean residue weight,
l represents the optical path length, and c
represents the concentration (g/ml).
The estimation of secondary structural elements was carried out by
deconvolution of the far-UV CD curves obtained in 100 mM phosphate buffer (pH 7.0) according to computerized procedures (16).
Data were obtained from the eight different CD spectra recorded for
each protein preparations (two protein batches per G6PD variant).
Intrinsic protein fluorescence spectra were recorded after excitation
at 295 nm, at 25 °C using 1.0-cm path length cuvettes.
Samples for 8-anilinonaphthalene-1-sulfonic acid (ANS) binding
measurements were prepared by adding 10 µM ANS to the
incubation mixtures of protein solutions at various concentrations of
urea. ANS fluorescence was monitored at 470 nm upon excitation at 350 nm using 1.0-cm path length cells. The percentage of
F0 in the native state was calculated from the
Fmax value of each variant.
Quenching of tryptophan fluorescence was conducted at 25 °C using
excitation and emission wavelengths of 295 and 340 nm, respectively. Samples were prepared by adding aliquots of 5 M KI to
native enzyme solutions. The Stern-Volmer constant
(KSV) was defined as follows,
|
(Eq. 2)
|
where F0 and F
correspond to fluorescence emission in the absence and presence of
quencher, respectively, and [Q] is the quencher concentration.
The accessible fraction of fluorophores was calculated from the
modified Stern-Volmer equation (17),
|
(Eq. 3)
|
This modified form of this equation permits
fa and KSV to be determined
graphically. A plot of F0/
F
versus 1/[Q] yields fa
1
as the intercept on the ordinate axis and (fa
KSV)
1 as the slope. The intercept
represents extrapolation to infinite quencher concentration (1/[Q] = 0). The value of F0/(F0
F) at this quencher concentration is the reciprocal of
the fluorescence quenched. At this concentration, only inaccessible
residues fluoresce.
Pyridoxal 5'-Phosphate (PLP) Experiments: Labeling, Quenching,
Polarization, and Fluorescence Energy Transfer--
Samples of G6PD
(0.4 mg/ml) were dialyzed and equilibrated at 4 °C against 0.1 M Hepes, pH 7.6, 9% glycerol, 0.2%
2-mercaptoethanol, and 1 mM EDTA. The samples were then
incubated in the dark at 25 °C with PLP under mild conditions
(100-fold molar excess) for 90 min as described elsewhere (18). The
Schiff base was reduced by the addition of an equivalent molar amount
of NaBH4 with respect to PLP as reported elsewhere (19).
The excess of PLP and NaBH4 in the samples was removed by
dialysis and equilibrated against 50 mM sodium phosphate
buffer, pH 7.0, and 1 mM EDTA.
Quenching of the fluorescence of n-
-pyridoxyllysine by KI
was carried out by adding aliquots of 5 M KI to the samples
of labeled enzyme. Readings were obtained at 25 °C using excitation and emission wavelengths of 330 and 390 nm, respectively. The Stern-Volmer constant was calculated as described above. Polarization values of the labeled enzyme were obtained from samples previously incubated at 25 °C with different urea concentrations for 2 h. Readings were recorded using 0.2-cm path length cuvettes at excitation and emission wavelengths of 330 and 390 nm, respectively.
Fluorescence energy transfer experiments were conducted at 25 °C
using 1.0-cm path length cuvettes. The excitation spectra of the
PLP-labeled G6PD variants were recorded at an emission wavelength of
390 nm. The energy transfer efficiency was calculated as follows,
|
(Eq. 4)
|
where FA and FAD
are the acceptor relative fluorescence intensities in the absence and
presence of the energy donor, respectively.
Distances were calculated according to Förster's equation
(20),
|
(Eq. 5)
|
where E represents the fluorescence energy transfer
efficiency and R0 is the critical distance at
which the transfer energy is 50%.
Differential Scanning Calorimetry (DSC) and Thermostability of
G6PD Activity--
Samples of the three G6PD variants at
concentrations of 1.50-2.2 mg/ml were dialyzed and equilibrated at
4 °C against 50 mM Hepes, pH 7.0, 0.02%
2-mercaptoethanol, 1 mM EDTA, 1 µM
-aminocaproic acid, 1 nM NADP, and 0.1 M
KCl. Calorimetric measurements were made at a scanning rate of
60 °C/h from 35 to 70 °C. OriginTM software (MicroCal Inc.,
Northampton, MA), using the algorithm for a non-two-state transition,
was employed to fit the unfolding thermograms as a single endothermic
peak and to obtain experimental values of unfolding enthalphy
(
H1), van't Hoff enthalpy
(
Hv1), and unfolding temperature (Tm). Briefly, the software conducts a nonlinear
least-square best fit using Marquardt algorithms, starting with the
user's initial estimation of the Tm value and
applying contrasted basic thermodynamic equations for thermotropic
transitions corresponding to biological molecules. Subsequently, the
values of the parameters are corrected to achieve the minimum value of
2. The iterative adjustment process is complete when the
2 value is not further diminished. For each thermogram,
the microcalorimeter generates 30-35 heat capacity experimental points
per degree centigrade. In these experiments, statistical significance
is guaranteed, since parametric fitting of the transition range of
protein denaturation (approximately 15 °C) involves at least 450 points. This procedure has been previously used for the
characterization of other proteins (21, 22).
For the thermostability analysis of G6PD activity, multiple enzyme
samples were heated in a thermocycler at a constant temperature increase rate of 1 °C/min. Tubes containing the samples were
manually removed from the thermocycler once a given temperature between 30 and 65 °C had been reached and immediately chilled on ice
(23).
 |
RESULTS AND DISCUSSION |
Changes in Secondary and Tertiary Structure--
To determine
whether some secondary or tertiary structural elements are affected in
G6PD A
, urea unfolding of the three G6PD variants (B, A,
and A
) was monitored by CD spectra in the far- and
near-UV ranges.
Unfolding transitions in the secondary structure of the variants were
monitored by the calculation of [
] at 222 nm, as a function of
urea concentration (24). The signal diminished at increasing denaturant
concentration (Fig. 1A). At
urea concentrations below 2 M, all three variants retained
about 90% of their secondary structure. The midpoint (50% of the
native CD signal) was achieved at 3.2 ± 0.2 M urea
for G6PD B and G6PD A, compared with 2.5 ± 0.1 M for
G6PD A
.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 1.
Plot of [ ] as a
function of urea concentration for G6PD B ( ), A ( ), and
A ( ). CD spectra were recorded at 25 °C in 10 mM Tris-HCl, pH 8.0, 5 mM EDTA, 0.02%
2-mercaptoethanol, 1 µM -aminocaproic acid, and 1 nM NADP using 0.2-cm path length cuvettes. Values of 50%
unfolding are given as the mean ± S.D. of two independent
experiments conducted in triplicate. The error
bars represent the S.D. range. The absence of error bars
indicates an S.D. below 4%. A, changes corresponding to the
far ultraviolet region recorded at 222 nm ([ ]222) in
the presence of 0-8 M urea. 50% unfolding was achieved at
3.2 ± 0.2 M urea in G6PD B and G6PD A and at 2.5 ± 0.1 M urea in G6PD A . B,
changes corresponding to the near-ultraviolet region recorded at 270 nm
([ ]270) in the presence of 0-8 M urea.
50% unfolding was observed at a very similar urea concentration in all
three G6PD variants (2.7 ± 0.2 M in G6PD B and
2.5 ± 0.1 M in G6PD A and G6PD
A ).
|
|
The extent of the positive band pattern recorded in the near-UV region
as a function of urea concentration permitted observation of unfolding
transitions in the tertiary structure (25), which, indeed, was reduced
as the denaturant concentrations increased (Fig. 1B). The
ellipticity signal, [
], at 270 nm for the native G6PD
A
was 60% lower than for the native G6PD B and G6PD A,
indicating reduced tertiary structure in the double mutant. At
concentrations of urea under 2 M, there were quantitative
differences in the tertiary structure retained: G6PD B, 85 ± 4%;
G6PD A, 75 ± 4%; and G6PD A
, 67 ± 4%.
Nevertheless, 50% unfolding of all three variants occurred at a very
similar urea concentration (2.7 ± 0.2 M for G6PD B
and 2.5 ± 0.1 M for G6PD A and G6PD
A
).
These results indicate that the loss of tertiary structure in G6PD B
and G6PD A occurred at lower urea concentrations than the disruption of
secondary structure. However, the presence of two mutations in G6PD
A
leads to a simultaneous disruption of the secondary and
tertiary structure, as exhibited by the identical 50% unfolding values recorded at 222 and 270 nm. This effect is quite unusual, since the
tertiary structure of globular proteins generally undergoes disruption
before the secondary structural elements (26, 27) and suggests the
highly unstable nature of the protein.
In addition, the far-UV CD spectra of the native proteins obtained in
100 mM phosphate buffer (pH 7.0) permitted estimation of
the secondary structural weights (16) of each G6PD variant as shown in
Table I. These values served to predict
specific structural shifts as point mutations were introduced into the enzyme. G6PD A slightly increased its
-sheet and
-turn content at
the expense of
-helices. A more dramatic secondary structural shift
was observed in G6PD A
, where, in comparison with G6PD A,
a 56% increase of
-sheet content with no modification in the amount
of
-helix was calculated.
View this table:
[in this window]
[in a new window]
|
Table I
Secondary structural weights
The percentage of secondary structure content of the three G6PD
variants was estimated by deconvolution of their respective far-UV CD
spectra (16). -Helix and -sheet weights were calculated from the
three-dimensional (3D) model of G6PD B (9). -Turn contents were
estimated using PROCHECKTM software, which determines this structural
element using the three-dimensional model coordinates (M. Adams,
personal communication).
|
|
The N126D mutation occurs in an
-helix (
C, Fig.
2) exposed to a polar aqueous
environment. The residues asparagine and aspartic acid show a fairly
similar low propensity to form
-helices (28, 29), while both have a
high conformational preference to form reverse turns (30). When the
secondary structure content is predicted by analytic vector
decomposition (31, 32) of the 14 amino acids of the
C stretch
(AASYQRLNSHMNAL) and compared with the mutant stretch
(AASYQRLNSHMDAL), both show identical
-helix contents
(100%). The solvation of the first four C-O main chain groups in an
-helix can differentially interact with the helix dipole, depending
on the nature of the C-cap residue (33, 34). Consequently, the N126D
substitution (2 residues away from the C-cap of the
C stretch) could
account for a subtle modification in the orientation of the helix and
thus increase its natural tendency to form a reverse turn. Indeed,
deconvolution of the CD far-UV spectra (Table I) revealed that the
N126D mutation in G6PD A resulted in a significant increase in
-turns and
-sheets at the expense of
-helices. This
experimental procedure is particularly efficient for calculating the
-helix content of proteins (35), and the present mean value (28.1%)
is in good agreement with that calculated for the human G6PD
three-dimensional model (27.5%) (9).

View larger version (46K):
[in this window]
[in a new window]
|
Fig. 2.
Model of the human G6PD monomer indicating
the position of the substitutions in G6PD A in the
corresponding secondary structural motifs (V68M in
-sheet B and N126D in
-helix C). Also highlighted are the
Lys205 in the active site and all of the protein's
tryptophan (W) residues.
|
|
The second mutation, V68M, which gives rise to the deficient G6PD
A
, did not induce a further loss of
-helix content, as
shown by CD spectra deconvolution, while a significant loosening of
-turns shifting to
-sheet was observed, indicating increased
rigidity in the
-sheet area of the mutations (Table I). This finding seems to be inconsistent with the comparative prediction of secondary structural content (31, 32) in the 7-residue peptide comprising
-sheet B in the wild type (TFIVGYA; 100%
) and in
the mutant (TFIMGYA; 75%
and 25% coil), suggesting
the higher
-sheet disruption potential of methionine (29, 36-38).
However, the predicted percentage of
-sheet loss in this short
stretch obviously cannot account for the large change in the CD
spectrum. This suggests that the loss of stability of
-sheet B must
generate changes in the relationship of this structure with neighboring
secondary motifs, which maintain the fold in this area. The forces that
stabilize
-turns in proteins are the hydrogen bonds between the acyl
oxygen of the first amino acid and the nitrogen-hydrogen bond of the
fourth amino acid in addition to the close proximity of the
-carbons
of the first and fourth residues, which are 0.5-0.6 nm apart (39). In
G6PD A and G6PD A
, the loss of
-turn content could be
explained in terms of minor changes in the spatial arrangement of some
residues induced by the mutations in the molecules. These mutations may
favor the stabilization of
-sheet structures in the disturbed area
of this coenzyme domain.
Hydrophobic Surface Exposure--
Hydrophobic interactions play a
major role in defining conformation and interactions between secondary
structural elements. The exposure of the hydrophobic surface of the
three variants during urea unfolding was monitored using the
hydrophobic probe, ANS. The affinity of ANS for protein molecules
significantly increases when the rigidity of the tertiary structure is
disrupted while the compactness of the secondary structure is retained
(40).
For the native proteins with no urea present, the fluorescence signal
obtained at 470 nm for G6PD A
(percentage of
F0 = 13.5 ± 1.7%) was slightly higher
than that corresponding to the nondeficient variants G6PD A (percentage of F0 = 9.8 ± 1.5%) and G6PD B
(percentage of F0 = 7.2 ± 0.8%). This is
indicative of a greater hydrophobic area accessible to ANS in the
deficient variant. Fig. 3 shows the
fluorescence emission ratio (F/F0) in
the presence of increasing concentrations of urea. During urea
unfolding, the three G6PD variants enhanced the fluorescence signal,
which reached its maximum at 3 M urea, although each
variant showed different maximum peak heights at this urea
concentration. With respect to the maximum peak height shown by the
native enzyme, 14.0 ± 1.5-, 10.4 ± 1.6-, and 7.5 ± 1.0-fold increases were recorded for G6PD B, G6PD A, and G6PD
A
, respectively, indicating a different degree of
hydrophobic surface exposure in each variant. Thus, the presence of the
N126D mutation alone in G6PD A leads to reduced ANS binding, which is
further reduced when the second mutation V68M in G6PD A
is present, indicating a progressive tendency toward loss in tertiary
structure (24) as mutations are introduced into the protein. This is in
agreement with the reduced amount of ellipticity signal at 270 nm in
the double mutant.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 3.
Hydrophobic surface exposure changes at
increasing urea concentrations in G6PD B ( ), A ( ), and
A ( ). ANS binding was estimated by fluorescence
at 470 nm using an excitation wavelength of 350 nm. Determinations were
performed at 25 °C in 10 mM Tris-HCl, pH 8.0, 5 mM EDTA, 0.02% 2-mercaptoethanol, 1 µM
-aminocaproic acid, and 1 nM NADP using 1.0-cm path
length cuvettes. F and F0 are the
fluorescence signal in the presence and absence of urea, respectively.
Maximum peak heights with respect to the native enzyme were obtained in
3 M urea. Values are expressed as the mean ± S.D. of
two independent measurements performed in triplicate. Error
bars represent the S.D. range. The absence of error bars
indicates an S.D. of less than 5%. Percentage maximum increments with
respect to the native state were 14.0 ± 1.5 for G6PD B, 10.4 ± 1.6 for G6PD A, and 7.5 ± 1.0 for G6PD A .
|
|
Thermodynamics of Unfolding--
Studies conducted on hydrophobic
mutants of proteins have shown the part played by hydrophobic residues
in protein stability (14). The changes in tertiary structure and
surface hydrophobicity observed in G6PD A
prompted us to
quantitatively explore the hydrophobic interactions stabilizing the
folded conformations of the three enzyme variants. Temperature-induced
unfolding was explored by DSC to evaluate the energetic and
thermodynamic mechanisms involved in the transition from the folded to
the unfolded state. Fig. 4A
shows the curves and thermodynamic variables corresponding to the
experimental unfolding process.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 4.
Thermal denaturation of the three G6PD
variants. A, DSC plots of the G6PD variants B
(solid line), A (dotted
line), and A (dashed
line) in 50 mM Hepes, pH 7.0, 0.02%
2-mercaptoethanol, 1 mM EDTA, 1 µM
-aminocaproic acid, 1 nM NADP, and 0.1 M
KCl. Scanning calorimetry was conducted from 35 to 70 °C at a
heating rate of 60 °C/h using sample concentrations of 1.50-2.20
mg/ml. Thermogram fitting and data analysis were performed using
OriginTM software (see "Experimental Procedures").
Tm, given in degrees Centigrade, and
H1 and Hv1
enthalpies, expressed in kcal/mol, are the mean ± S.D. of
triplicate determinations (see "Experimental Procedures" for
details on statistical significance). Hv1
mainly takes into account intramolecular interactions within the
polypeptide chain, and H1 reflects these
intramolecular interactions plus interactions of the polypeptide chain
with the environment (41). B, loss of residual enzymatic
activity according to temperature in G6PD B ( ), A ( ), and
A ( ). Several protein samples were heated from 30 to
65 °C in a thermocycler at a rate of 1 °C/min. The
protein-containing tubes were removed at a given temperature and
chilled on ice. G6PD activity was determined spectrophotometrically at
340 nm as described under "Experimental Procedures." Results are
expressed as the percentage of maximum activity ± S.D. of two
independent measurements conducted in triplicate. Error
bars represent the S.D. range. The absence of error bars
indicates an S.D. of less than 2%. Estimated T1/2
values in degrees Centigrade were 57.0 ± 0.3 for G6PD B,
57.0 ± 0.5 for G6PD A, and 55.2 ± 0.2 for G6PD
A .
|
|
Although the Tm and
Hv1 values were
practically identical for each variant,
H1
values showed a major difference. The energy released by G6PD
A
was half that released by G6PD B and G6PD A, which were
in turn very similar. Moreover, although the calculated
Hv1 values for the three variants were
similar, the
H1/
Hv1
ratio corresponding to G6PD A
was less than 1 (0.48),
while those corresponding to G6PD B and G6PD A were close to unity. The
van't Hoff enthalpy value reflects intramolecular interactions within
the polypeptide chain (41), while unfolding enthalpy is a more general
thermodynamic parameter that also takes into account interactions of
the protein with the environment (41). This indicates that in both
nondeficient G6PD variants, the transition follows a basic model of
unfolding in two states, while the unfolding process in G6PD
A
reflects cooperativity between the two subunits of the
dimer (30). Moreover, the thermal unfolding process was observed to be
essentially irreversible in all three variants (data not shown). Since
no disruptive effect was observed in G6PD A in comparison with G6PD B,
the DSC peaks allowed us to attribute a synergistic destructurization
effect to the second mutation. Therefore, the N126D substitution in
G6PD A appears to have no effect on the dimeric structure, as shown by
the practical absence of modifications in the DSC thermograms and also
in the CD spectra discussed above. Hydrophobic interactions are a major
stabilizing factor of folded conformations in proteins (42, 43), and
correlation between changes in the Gibbs energy and hydrophobic surface
exposure upon denaturation has been previously attributed to point
mutations in proteins (14, 44). It would therefore seem that the
portion of loosened tertiary structure permits the entrance of a
certain additional amount of water into the dimer of the double mutant, as detected by the enhanced binding of ANS to the hydrophobic surface.
The progressive increase in area of hydrophobicity as each mutation is
introduced into the G6PD molecule (see Fig. 3) indicates that the final
synergistic structural disruption effect observed by CD and DSC in G6PD
A
is probably the consequence of several preceding
changes in the molecular environment, including hydrophobicity.
In order to determine if the destructurization of the molecule occurred
at a similar temperature to that corresponding to the global unfolding
process, we conducted a series of experiments to estimate the retention
of residual enzyme activity in the temperature range of 30-65 °C
(Fig. 4B). Again, both G6PD B and G6PD A exhibited very
similar behavior as the temperature increased, while the loss of G6PD
A
activity was apparent even at low temperatures.
From 30 to 50 °C, G6PD B and G6PD A retained 100% enzyme activity,
while G6PD A
exhibited 79.0 ± 1.0% retention.
Additionally, in the double mutant, the 50% inactivation temperature
(T1/2) was approximately 2 °C lower than that
corresponding to G6PD B and G6PD A (55.2 ± 0.2 °C
versus 57.0 ± 0.3 and 57.0 ± 0.5 °C, respectively). Thus, the loss in activity of the three variants appears
to be concurrent with the unfolding of the protein structure, since
both melting temperatures (T1/2 and
Tm) were practically the same.
Microenvironment--
Urea stability assays, in which G6PD
activity was monitored in each variant, were conducted (Fig.
5A). Only slight differences were observed in the residual enzyme activity at identical enzyme concentrations (0.2 mg/ml), and up to 2 M urea with 24 ± 3, 29 ± 2, and 38 ± 1% losses in activity was recorded
for the B, A, and A
variants, respectively. The most
dramatic decay in enzyme activity was observed from 2 to 2.5 M urea, with 68.5 ± 0.5, 82.5 ± 2.5, and
86 ± 3% activity losses recorded at 2.5 M urea for
G6PD B, A, and A
, respectively. G6PD A
showed undetectable activity in 3 M urea, while the
remaining variants still exhibited some activity at urea concentrations of 3 M (G6PD B, 7.0 ± 2.0%; G6PD A, 1.5 ± 0.3%).

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 5.
Influence of increasing concentrations of
urea on intrinsic fluorescence emission and residual activity loss in
G6PD B ( ), A ( ), and A ( ). Experiments were
conducted at 25 °C in 10 mM Tris-HCl, pH 8.0, 5 mM EDTA, 0.02% 2-mercaptoethanol, 1 µM
-aminocaproic acid, and 1 nM NADP. A, G6PD
activity according to urea concentration (0-3.5 M).
Results are expressed as percentages ± S.D. with respect to the
activity of the enzymes in the absence of urea determined in two
independent experiments conducted in triplicate. Error
bars represent the S.D. range. The absence of error bars
indicates an S.D. of less than 3%. G6PD activity was detected
spectrophotometrically at 340 nm as described under "Experimental
Procedures." The urea concentration at which a 50% activity loss was
recorded was 2.33 ± 0.02 for G6PD B, 2.21 ± 0.01 for G6PD
A, and 2.13 ± 0.01 for G6PD A . B, plot
of intrinsic fluorescence emission maxima according to the urea
concentration (0-8 M). Spectra were recorded at excitation
and emission wavelengths of 295 and 310-400 nm, respectively, in
1.0-cm path length cuvettes. emission maxima determined in two
independent experiments (conducted in triplicate) in the absence of
urea were 344 nm for G6PD B, 346 nm for G6PD A, and 347 nm for G6PD
A . Error bars represent the S.D.
range.
|
|
Human G6PD has 7 tryptophan residues/monomer. These are not mutated in
either the A or A
variant. According to the
three-dimensional model proposed for human G6PD, three of these
residues (Trp53, Trp54, and Trp164)
are found in the coenzyme domain, where the mutations N126D and V68M
are located. Fluorescence emission maxima served to monitor modifications in the microenvironment of the tryptophan residues during
unfolding. The emission maxima of the native proteins were 344 nm for
G6PD B, 346 nm for G6PD A, and 347 nm for G6PD A
. In the
presence of increasing concentrations of urea, a red shift was produced
in the emission spectra, reflecting the gradual exposure of the
tryptophan residues to the solvent (Fig. 5B). Shifts of 10, 8, and 7 nm were recorded for the B, A, and A
variants,
respectively. These displacements of maximum emission toward the red
region of the spectrum suggest a slight difference in the
microenvironment of some of the tryptophan residues in G6PD B with
respect to G6PD A and G6PD A
, with the highest degree of
tryptophan exposure in the native state exhibited by the double mutant
G6PD A
. Both A and A
showed a linear
displacement of emission maxima with rising urea concentration (0-8
M), while in the normal G6PD B this took place in three
phases, with an initial stage from 0 to 2 M urea. The second phase, observed in the narrower range of 2-2.5 M
urea, involved a 2.5-nm shift in G6PD B. The third linear phase from 2.5 to 8 M urea was of a similar slope in the three
species. The shift in the emission maximum from 2 to 2.5 M
urea in G6PD B (Fig. 5B) is associated with the dramatic
activity loss in the three variants (Fig. 5A), although this
shift in fluorescence was inappreciable in the A and A
variants. These findings suggest that the microenvironment of some of
the tryptophan residues of the A and A
variants differs
substantially from that of the nondeficient G6PD B in native conditions
but does not appear to have a notable effect on catalysis or stability
(10, 11).
To further assess the degree of differential exposure of tryptophan
residues in the three variants, quenching of intrinsic tryptophan
fluorescence was studied, and the accessible fraction fa was calculated. The iodide anion is able to
quench only the most solvent-exposed residues, whereas acrylamide can penetrate the protein matrix to a certain extent and is therefore capable of additionally quenching tryptophan fluorescence of residues hidden in dynamic structures of high flexibility (45).
The Stern-Volmer plot (Fig.
6A) exhibits a downward curve
indicating the existence of two populations of tryptophan residues with
different degrees of accessibility (17, 45). However, no difference in
the degree of quenching was observed between the A and B variants,
although variant A
did show a less pronounced downward
curve in the quenching course, suggesting the greater degree of
accessibility of some of the tryptophan residues in this variant. Given
the two populations of tryptophan residues with different degrees of
accessibility, we replotted the data according to a modified
Stern-Volmer equation that permits the graphical determination of the
fa of the tryptophan population and the
KSV value of the accessible fraction (Fig.
6B). The values of fa and
KSV obtained in the KI quenching of the
intrinsic fluorescence of each variant (Fig. 6B) were
notably higher than those reported for several other globular proteins
(26). As indicated by the fa value (17), iodide only
had access to less than 3 tryptophan residues out of the 7 in each
monomer in the B and A variants. In contrast, the structure of variant
A
permitted the access to almost 4 tryptophan
residues/monomer.

View larger version (12K):
[in this window]
[in a new window]
|
Fig. 6.
Quenching of tryptophan fluorescence by
iodide in G6PD B ( ), A ( ), and A ( ).
A, Stern-Volmer plot of tryptophan fluorescence quenching by
iodide in native conditions recorded at 25 °C in 10 mM
Tris-HCl, pH 8.0, 5 mM EDTA, 0.02% 2-mercaptoethanol, 1 µM -aminocaproic acid, and 1 nM NADP using
1.0-cm path length cuvettes. Excitation and emission wavelengths were
295 and 340 nm, respectively. Experiments consisted of two independent
assays conducted in triplicate. Error bars
represent the S.D. range. The absence of error bars indicates an S.D.
of less than 4%. B, modified Stern-Volmer plot of
fluorescence quenching of the G6PD variants by KI, indicating the
fa of the tryptophan population. The values of
fa, expressed as the mean ± S.D. of two
independent experiments conducted in triplicate were calculated as
described under "Experimental Procedures." The experimental
fa values for each variant were 0.33 ± 0.02 (G6PD B), 0.40 ± 0.02 (G6PD A), and 0.60 ± 0.10 (G6PD
A ). The respective calculated KSV
values were 3.47 ± 0.10 M 1 (G6PD B),
3.41 ± 0.03 M 1 (G6PD A), and 2.33 ± 0.80 M 1 (G6PD
A ). Error bars
represent the S.D. range. The absence of error bars indicates an S.D.
of less than 4%.
|
|
Active Site Geometry--
The loss of G6PD A
activity at slightly lower urea concentration and temperature in the
denaturation experiments (see Figs. 4B and 5A)
prompted us to further analyze the effect of the double mutant on the
active site. The lysine residue at position 205 in G6PD has been shown
to be essential for the catalysis of glucose 6-phosphate to
6-phosphoglucono-
-lactone (46). This residue can be specifically
labeled with the fluorescent probe PLP (18). The behavior of this
residue within the active site in its interaction with nearby residues
was monitored by quenching of pyridoxamine fluorescence and
polarization of the pyridoxamine group during unfolding in the three variants.
The Stern-Volmer plots of PLP quenching in the three variants yielded
straight lines permitting the calculation of the respective KSV values: 10.53 ± 0.29 M
1 for G6PD B, 10.86 ± 0.60 M
1 for G6PD A, and 10.62 ± 0.67 M
1 for G6PD A
(Fig.
7A). The virtually identical
KSV constants indicate that the long carbon
chain of Lys205 constraining the
-amine group has a very
similar degree of flexibility and shows similar accessibility in the
three variants. Moreover, there seemed to be no difference in the local
interaction pattern of this residue in the variants, suggesting that
the three-dimensional structure shaping the active site was unaffected
by the mutations at positions 126 and 68.

View larger version (11K):
[in this window]
[in a new window]
|
Fig. 7.
Fluorescence of PLP-labeled lysine 205 in
G6PD B ( ), A ( ), and A ( ). The labeling
method is described under "Experimental Procedures." A,
Stern-Volmer plot of n- -pyridoxyllysine fluorescence
quenching by iodide in native conditions. Quenching was performed at
25 °C in 50 mM sodium phosphate, pH 7.0, and 1 mM EDTA using excitation and emission wavelengths of 330 and 390 nm, respectively. KSV values were
calculated as described under "Experimental Procedures" and are
expressed as means ± S.D. of two independent determinations
conducted in triplicate: 10.53 ± 0.29 M 1 for G6PD B, 10.86 ± 0.60 M 1 for G6PD A, and 10.62 ± 0.67 M 1 for G6PD A . Error
bars represent the S.D. range. The absence of error bars
indicates an S.D. of less than 2%. B, polarization of
n- -pyridoxyllysine fluorescence according to urea
concentration. Readings were obtained at excitation and emission
wavelengths of 330 and 390 nm, respectively, using 0.2-cm path length
cuvettes. Unfolding transitions were detected at 2.90 ± 0.04 M urea in G6PD B, 2.70 ± 0.03 M in G6PD
A, and 2.50 ± 0.04 M in G6PD A . Results
are expressed as the mean ± S.D. of two independent assays
conducted in triplicate. Error bars represent the
S.D. range. The absence of error bars indicates an S.D. of less than
3%.
|
|
Moreover, in the native state, all of the three variants showed a
pyridoxyllysine 205 polarization of fluorescence value of 0.248 ± 0.002 (Fig. 7B). These findings confirmed those of the quenching experiments and support the idea of an unmodified active site
microenvironment in the mutant proteins with respect to normal G6PD B.
Polarization of fluorescence values fell from 0.248 ± 0.002 to
0.148 ± 0.003 in G6PD B and G6PD A and to 0.137 ± 0.006 in G6PD A
as the urea concentration increased to 5 M. Unfolding transitions, estimated as the urea
concentration at which the polarization signal is 50% of the maximum,
were different for each variant: 2.90 ± 0.04 M for
G6PD B, 2.70 ± 0.03 M for G6PD A, and 2.50 ± 0.03 M for G6PD A
(Fig. 7B). This
indicates, once again, that the double mutation in the A
variant gives rise to a less stable protein structure. Up to a urea
concentration of 2 M, the polarization changes were
relatively small as compared with the maximum change (0.016 ± 0.001 for B, 0.031 ± 0.004 for A, and 0.033 ± 0.005 for
A
), reflecting disturbances in the tertiary structure of
the active site. Greater polarization changes were observed from 2 M urea onwards (0.084 ± 0.005 for G6PD B, 0.070 ± 0.005 for A, and 0.08 ± 0.007 for G6PD A
),
suggesting further similar modifications in the secondary structure of
the active site.
Topology of the Coenzyme Domain--
In the active site of G6PD,
Lys205 is less than 20 Å away from Trp53 and
Trp54 (9). Moreover, these residues are at an equivalent
distance from the V68M mutation in the three-dimensional model (see
Fig. 2). Specific labeling of Lys205 and the fact that the
structure of the active site is not modified in any of the variants
permitted the study of the conformational differences that the
mutations could cause in the coenzyme domain around tryptophan residues
53 and 54 in the A and A
variants. Indeed, fluorescence
energy transfer measurements between tryptophan residues and
n-
-pyridoxyllysine have been previously used to calculate
inner distances in several proteins (47, 48). We directly measured
fluorescence energy transfer in a single excitation spectrum, given the
fluorescence properties of the acceptor PLP. The critical distance at
which 50% of the excitation energy is transferred to PLP from
tryptophan has been calculated as 21 Å for this pair of
chromophores (49). Since Trp53 and Trp54 are
the only tryptophan residues at least 20 Å from PLP, it is assumed
that the possible contribution of the other five tryptophan residues is
minimal, since the capacity of excitation energy transfer decreases
exponentially with distance (50). Nevertheless, in our system it was
not possible to discern the individual energy transfer contribution of
Trp53 and Trp54 (see Fig. 2), since these
probably behave as a single transfer unit to PLP. The energy transfer
efficiency shown by each variant (Fig. 8)
decreased as point mutations were incorporated into the native G6PDs,
clearly indicating that the distance between the Trp53-Trp54 transfer unit and the PLP-labeled
Lys205 is greater in the mutant enzymes (G6PD
A
> G6PD A) than in the normal G6PD B.

View larger version (22K):
[in this window]
[in a new window]
|
Fig. 8.
Fluorescence energy transfer efficiency from
tryptophan residues to PLP-labeled lysine 205 in G6PD B
(solid line), A (dotted
line), and A (dashed
line). Excitation spectra were obtained at an
emission wavelength of 390 nm using an excitation wavelength of
260-380 nm. The labeling method, efficiency of energy transfer, and
distances calculations are described under "Experimental
Procedures." The percentage of energy transfer efficiency permitted
calculation of the mean distance (R), in Å, from the
Trp53-Trp54 unit to PLP Lys205 (see
"Results and Discussion"). Values are expressed as mean ± S.D. of two independent assays conducted in triplicate.
|
|
The in vitro process of refolding to obtain a catalytically
active molecule does not entirely correspond to the in vivo
folding process. In vitro, folding is less efficient and
often requires physicochemical conditions different from those of the
intracellular environment. Furthermore, refolding assays involve the
whole polypeptide chain, whereas, in vivo, polypeptide
folding may start as soon as the N-terminal portion of the nascent
chain emerges from the ribosome (51). It has been previously reported
that the N126D mutation alone does not affect the in vitro
refolding of G6PD A, while the additional presence of the second
mutation V68M in G6PD A
poses a serious constraint to the
productive refolding of the protein (13). The onset of in
vitro refolding has been associated with the simultaneous collapse
of hydrophobic motifs buried within the molecule, the formation of
stable secondary structures providing the necessary architecture for
the subsequent folding and the formation of covalent bonds (S-S
bridges) stabilizing the polypeptide in a given favorable folding
conformation (52-55).
In conclusion, it would appear that the combination of changes in
hydrophobic surface exposure, shifts in secondary structural elements,
and displacements of domains by misinteractions in the deficient G6PD
A
lead to a modified, less stable conformation with
altered topology, which shifts the intracelular equilibrium between
unfolded/denatured and folded/native states. In the anuclear red blood
cell, this results in a 90% reduction of active molecules of G6PD
A
.
 |
ACKNOWLEDGEMENTS |
Thanks are due to Susana Perez-Benavente for
excellent technical assistance, to Dr. Philip Mason (Imperial College,
School of Medicine, London) and Dr. Margaret Adams (University of
Oxford, Oxford) for useful discussions on G6PD deficiency mechanisms, to Prof. Carlos Gutierrez-Merino (Universidad de Extremadura, Badajoz)
for help and for the provision of the microcalorimeter, to Prof.
Francisco García-Blanco and Dr. Susana Corrales (Universidad Complutense de Madrid (UCM) Madrid) for providing the CD spectrometer and for help, and to Dr. Alvaro Martinez del Pozo (UCM, Madrid) for use
of the deconvolution software.
 |
FOOTNOTES |
*
This work was supported by Fondo de Investigaciones
Sanitarias Grant 92/1179 and by British Council/Acciones Integradas
Grant HB1996-0178.The costs of publication of this
article were defrayed in part by the
payment of page charges. The article
must therefore be hereby marked
"advertisement" in
accordance with 18 U.S.C. Section
1734 solely to indicate this fact.
This paper is dedicated to the memory of Prof. Jorge E. Churchich, who
enthusiastically proposed the ANS binding experiments.
To whom correspondence should be addressed: Departamento de
Bioquímica y Biología Molecular IV, Universidad
Complutense de Madrid, Facultad de Veterinaria, Ciudad Universitaria,
28040 Madrid, Spain. Tel.: 34 91 3943827; Fax: 34 91 3943824; E-mail: bauchem@eucmax.sim.ucm.es.
 |
ABBREVIATIONS |
The abbreviations used are:
G6PD, glucose-6-phosphate dehydrogenase;
ANS, 8-anilinonaphthalene-1-sulfonic
acid;
PLP, pyridoxal 5'-phosphate;
DSC, differential scanning
calorimetry.
 |
REFERENCES |
| 1.
|
Vulliamy, T.,
Luzzatto, L.,
Hirono, A.,
and Beutler, E.
(1997)
Blood Cells Mol. Dis.
23,
302-313[CrossRef][Medline]
[Order article via Infotrieve]
|
| 2.
|
Vulliamy, T.,
Mason, P. J.,
and Luzzatto, L.
(1992)
Trends Genet.
8,
138-143[Medline]
[Order article via Infotrieve]
|
| 3.
|
Bienzle, U.,
Ayeni, O.,
Lucas, A. O.,
and Luzzatto, L.
(1972)
Lancet
1,
107-110[Medline]
[Order article via Infotrieve]
|
| 4.
|
Ruwende, C.,
Khoo, S. C.,
Snow, R. W.,
Yates, S. N.,
Kwiatkowski, D.,
Gupta, S.,
Warn, P.,
Allsopp, C. E.,
Gilbert, S. C.,
Peschu, N.,
Newbold, C. I.,
Greenwood, B. M.,
Marsh, K.,
and Hill, A. V. S.
(1995)
Nature
376,
246-249[CrossRef][Medline]
[Order article via Infotrieve]
|
| 5.
|
Bautista, J. M.,
and Luzzatto, L.
(1997)
in
Protein Dysfunction in Human Genetic Disease
(Swallow, D. M.
, and Edwards, Y. H., eds)
, pp. 33-56, BIOS Scientific Publishers Ltd., Oxford
|
| 6.
|
Babalola, O.,
Cancedda, R.,
and Luzzatto, L.
(1972)
Proc. Natl. Acad. Sci. U. S. A.
69,
946-950[Abstract/Free Full Text]
|
| 7.
|
Hirono, A.,
and Beutler, E.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
3951-3954[Abstract/Free Full Text]
|
| 8.
|
Vulliamy, T. J.,
D'Urso, M.,
Battistuzzi, G.,
Estrada, M.,
Foulkes, N. S.,
Martini, G.,
Calabro, V.,
Poggi, V.,
Giordano, R.,
Town, M.,
Luzzatto, L.,
and Persico, M. G.
(1988)
Proc. Natl. Acad. Sci. U. S. A.
85,
5171-5175[Abstract/Free Full Text]
|
| 9.
|
Naylor, C. E.,
Rowland, P.,
Basak, A. K.,
Gover, S.,
Mason, P. J.,
Bautista, J. M.,
Vulliamy, T. J.,
Luzzatto, L.,
and Adams, M. J.
(1996)
Blood
87,
2974-2982[Abstract/Free Full Text]
|
| 10.
|
Luzzatto, L.,
and Afolayan, A.
(1971)
Biochemistry
10,
420-423[CrossRef][Medline]
[Order article via Infotrieve]
|
| 11.
|
Babalola, O. G.,
Beetlestone, J. G.,
and Luzzatto, L.
(1976)
J. Biol. Chem.
251,
2993-3002[Abstract/Free Full Text]
|
| 12.
|
Town, M.,
Bautista, J. M.,
Mason, P. J.,
and Luzzatto, L.
(1992)
Hum. Mol. Genet.
1,
171-174[Abstract/Free Full Text]
|
| 13.
|
Gómez-Gallego, F.,
Garrido-Pertierra, A.,
Mason, P. J.,
and Bautista, J. M.
(1996)
FASEB J.
10,
153-158[Abstract]
|
| 14.
|
Takano, K.,
Yamagata, Y.,
Fujii, S.,
and Yutani, K.
(1997)
Biochemistry
36,
688-698[CrossRef][Medline]
[Order article via Infotrieve]
|
| 15.
|
Bautista, J. M.,
Mason, P. J.,
and Luzzatto, L.
(1992)
Biochim. Biophys. Acta
1119,
74-80[CrossRef][Medline]
[Order article via Infotrieve]
|
| 16.
|
Perczel, A.,
Hollósi, M.,
Tunády, G.,
and Fasman, G.
(1991)
Protein Eng.
4,
669-679[Abstract/Free Full Text]
|
| 17.
|
Lakowicz, J. R.
(1986)
Principles of Fluorescence Spectroscopy
, 3rd Ed.
, Plenum Press, New York
|
| 18.
|
Camardella, L.,
Caruso, C.,
Rutigliano, B.,
Romano, M.,
Di Prisco, G.,
and Descalzi-Cancedda, F.
(1988)
Eur. J. Biochem.
171,
485-489[Medline]
[Order article via Infotrieve]
|
| 19.
|
Camardella, L.,
Romano, M.,
Di Prisco, G.,
and Descalzi-Cancedda, F.
(1981)
Biochem. Biophys. Res. Commun.
103,
1384-1389[Medline]
[Order article via Infotrieve]
|
| 20.
|
Förster, X.
(1965)
in
Modern Quantum Chemistry
(Sinanoglu, O., ed), Vol. III
, pp. 93-137, Academic Press, Inc., New York
|
| 21.
|
Gutierrez-Merino, C.,
Molina, A.,
Escudero, B.,
Díez, A.,
and Laynez, J.
(1989)
Biochemistry
28,
3398-3406[CrossRef][Medline]
[Order article via Infotrieve]
|
| 22.
|
Centeno, F.,
Fernández-Salguero, P.,
Laynez, J. L.,
and Gutierrez-Merino, C.
(1992)
J. Bioenerg. Biomembr.
24,
625-634[CrossRef][Medline]
[Order article via Infotrieve]
|
| 23.
|
Scopes, D. A.,
Bautista, J. M.,
Naylor, C. E.,
Adams, M. J.,
and Mason, P. J.
(1998)
Eur. J. Biochem.
251,
382-388[Medline]
[Order article via Infotrieve]
|
| 24.
|
Gross, M.,
Lustig, A.,
Wallimann, T.,
and Furter, R.
(1995)
Biochemistry
34,
10350-10357[CrossRef][Medline]
[Order article via Infotrieve]
|
| 25.
|
Fersht, A. R.
(1994)
Biochem. Soc. Trans.
22,
267-273[Medline]
[Order article via Infotrieve]
|
| 26.
|
Gross, M.,
Furter-Graves, E. M.,
Wallimann, T.,
Eppenberger, H. M.,
and Furter, R.
(1994)
Protein Sci.
3,
1058-1068[Abstract]
|
| 27.
|
Couthon, F.,
Clottes, E.,
Ebel, C.,
and Vial, C.
(1995)
Eur. J. Biochem.
24,
160-170
|
| 28.
|
Blaber, M.,
Zhang, X. J.,
and Matthews, B. W.
(1993)
Science
260,
1637-1640[Abstract/Free Full Text]
|
| 29.
|
Chou, P. Y.,
and Fasman, G. D.
(1978)
Adv. Enzymol.
47,
45-148
|
| 30.
|
Creighton, T. E.
(1993)
Proteins: Structures and Molecular Properties
, 2nd Ed.
, pp. 255-257, W. H. Freeman and Co., New York
|
| 31.
|
Eisenhaber, F.,
Imperiale, F.,
Argos, P.,
and Frommel, C.
(1996)
Proteins
25,
157-168[CrossRef][Medline]
[Order article via Infotrieve]
|
| 32.
|
Eisenhaber, F.,
Frommel, C.,
and Argos, P.
(1996)
Proteins
25,
169-179[CrossRef][Medline]
[Order article via Infotrieve]
|
| 33.
|
Hol, W. G.,
van Duijnen, P. T.,
and Berendsen, H. J.
(1978)
Nature
273,
443-446[CrossRef][Medline]
[Order article via Infotrieve]
|
| 34.
|
Serrano, L.,
Sancho, J.,
Hirshberg, M.,
and Fersht, A. R.
(1992)
J. Mol. Biol.
227,
544-559 |